- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ONKURE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.01. | Reneo Pharmaceuticals-Aktie fällt auf 52-Wochen-Tief von 7,64 US-Dollar | 1 | Investing.com Deutsch | ||
| 10.01. | Reneo Pharmaceuticals stock hits 52-week low at $7.64 | 1 | Investing.com | ||
| 23.12.24 | Reneo Pharmaceuticals-Aktie erreicht 52-Wochen-Tief bei 7,91 US-Dollar | - | Investing.com Deutsch | ||
| 23.12.24 | Reneo Pharmaceuticals stock hits 52-week low at $7.91 | 1 | Investing.com | ||
| 10.12.24 | OnKure reports positive early trial data for cancer drug OKI-219 | 1 | Investing.com | ||
| 10.12.24 | OnKure meldet positive frühe Studiendaten für Krebsmedikament OKI-219 | 3 | Investing.com Deutsch | ||
| 10.12.24 | OnKure Therapeutics, Inc.: OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 | 61 | GlobeNewswire (Europe) | -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated... ► Artikel lesen | |
| 10.12.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | OnKure Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11.24 | OnKure Therapeutics, Inc.: OnKure Announces New Date for Upcoming Investor Call | 3 | GlobeNewswire (USA) | ||
| 07.11.24 | OnKure Therapeutics announces accounting firm change | 5 | Investing.com | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.24 | OnKure Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.11.24 | OnKure Therapeutics, Inc.: OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium | 2 | GlobeNewswire (USA) | ||
| 25.10.24 | vTv Therapeutics ends key license agreement with OnKure | 2 | Investing.com | ||
| 23.10.24 | OnKure files to sell 2.94M shares of Class A Common Stock for holders | 4 | Seeking Alpha | ||
| 10.10.24 | Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm | 1 | Benzinga.com | ||
| 10.10.24 | OnKure started at outperform by Oppenheimer, OKI-219 potential cited | 2 | Seeking Alpha | ||
| 10.10.24 | OnKure shares initiated with Outperform rating on drug potential | 2 | Investing.com | ||
| 08.10.24 | OnKure Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,975 | -0,04 % | Pfizer Aktie: Was Analysten zu berichten haben | Die US-amerikanische Pharmafirma Pfizer steht aktuell vor wichtigen strategischen Veränderungen. Der Konzern plant bedeutende Verkaufsaktivitäten, während die Aktie am letzten Handelstag bei 26,31 USD... ► Artikel lesen | |
| SANOFI | 98,87 | -0,32 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi nach einer Pharmakonferenz auf "Neutral" mit einem Kursziel von 105 Euro belassen. Mit der Veröffentlichung der Quartalszahlen... ► Artikel lesen | |
| INNOCAN PHARMA | 0,119 | +3,48 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| ASSEMBLY BIOSCIENCES | 13,700 | -3,52 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B | - ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed - - In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,880 | -1,40 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis | SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD... ► Artikel lesen | |
| ROYALTY PHARMA | 28,940 | +0,17 % | Royalty Pharma plc: Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program | Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 34,090 | -0,96 % | AKTIONÄR-Favorit BridgeBio mit Kurssprung - Startschuss zur Rally? | Das neue Jahr hätte für das US-Biotech-Unternehmen BridgeBio Pharma nicht besser starten können. Am Montag gelang dem Papier ein Kurssprung von 16 Prozent und damit ein neues Kaufsignal für die Aktie.... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 11,000 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors | NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today... ► Artikel lesen | |
| SOLIGENIX | 2,490 | +3,75 % | SOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma | FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company... ► Artikel lesen | |
| KALA BIO | 7,375 | -0,14 % | KALA BIO, Inc. (NASDAQ:KALA) CFO Sells $13,016.78 in Stock | ||
| ACLARIS THERAPEUTICS | 2,490 | +0,28 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| NEUROGENE | 16,100 | +5,23 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 20.11.2024 | The following instruments on XETRA do have their first trading 20.11.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.11.2024
Aktien
1 PLRNBWT00031 Rainbow Tours S.A.
2... ► Artikel lesen | |
| ESSA PHARMA | 1,710 | 0,00 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,530 | 0,00 % | Iterum Therapeutics PLC: Iterum Therapeutics Regains Full Nasdaq Compliance | DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,193 | 0,00 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen |
Das Unternehmen ONKURE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,210 (-3,56 %) liegt der Kurs bei 5,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONKURE THERAPEUTICS INC finden Sie auf Wallstreet Online.
